The effect of zoledronate-hydroxyapatite nanocomposites on osteoclasts and osteoblast-like cells in vitro

Biomaterials

Volumn 33, Issue 2, 2012, Pages 722-730

  Boanini, Elisa ^a   Torricelli, Paola ^b   Gazzano, Massimo ^c   Fini, Milena ^b   Bigi, Adriana ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c CNR   (Italy)

Author keywords

Bisphosphonates; Co cultures; Hydroxyapatite; Osteoblast; Osteoclast

Indexed keywords

BISPHOSPHONATES; C-AXIS DIRECTION; CASPASE-3; CO-CULTURES; CRYSTAL DIMENSIONS; CRYSTALLINE DOMAINS; DIRECT SYNTHESIS; HYDROXYAPATITE NANOCRYSTALS; IN-VITRO; OSTEOBLAST PROLIFERATION; OSTEOBLAST-LIKE CELLS; OSTEOCLAST; OSTEOCLAST PROLIFERATION; POWDER X RAY DIFFRACTION; PREFERENTIAL INTERACTION; PROFILE FITTING; SINGLE-CRYSTALLINE; STRUCTURAL MODIFICATIONS; STRUCTURAL SIMILARITY; UNIT CELLS;

CELL CULTURE; CELL DEATH; COBALT; CRYSTALLINE MATERIALS; DIFFRACTION; HYDROXYAPATITE; NANOCOMPOSITES; NANOCRYSTALS; X RAY DIFFRACTION;

APATITE;

BISPHOSPHONIC ACID DERIVATIVE; CASPASE 3; HYDROXYAPATITE; NANOCOMPOSITE; NANOCRYSTAL; ZOLEDRONIC ACID;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMICAL INTERACTION; COCULTURE; CONTROLLED STUDY; CRYSTAL STRUCTURE; HUMAN; HUMAN CELL; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; SYNTHESIS; X RAY DIFFRACTION;

ALENDRONATE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DIPHOSPHONATES; DURAPATITE; HUMANS; IMIDAZOLES; MICROSCOPY, ELECTRON, SCANNING; NANOCOMPOSITES; NANOPARTICLES; OSTEOBLASTS; OSTEOCLASTS; X-RAY DIFFRACTION;

EID: 80055110896     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.09.092     Document Type: Article

References (65)

1. Russell R.G.G. Bisphosphonates: the first 40 years. Bone 2011, 49:2-19.
2. Russell R.G.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759.
3. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003, 9:2643-2658.
4. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001, 296:235-242.
5. Van Beck E.R., Lowik C.W.G.M., Papapoulos S.E. Bone 2002, 30:64-70.
6. Ebetino F.H., Hogan A.M.L., Sun S., Tsoumpra M.K., Duan X., Triffitt J.T., et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone 2011, 49:20-33.
7. Rogers M.J., Crockett J.C., Coxon F.P., Mönkkönen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011, 49:34-41.
8. Russell R.G.G., Rogers M.J. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999, 25:97-106.
9. Compston J.E. The therapeutic use of bisphosphonates. Br Med J 1994, 309:711-715.
10. Martin T.J., Grill V. Bisphosphonates-mechanisms of action. Aust Prescr 2000, 23:130-132.
11. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 38:617-627.
12. Rogers M.J. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int 2004, 75:451-461.
13. Henneman Z.J., Nancollas G.H., Ebetino F.H., Russell R.G., Phipps R.G. Bisphosphonate bone affinity as assessed by inhibition of carbonated apatite dissolution in vitro. J Biomed Mater Res A 2008, 85A:993-1000.
14. Lawson M.A., Xia Z., Barnett B.L., Triffitt J.T., Phipps R.J., Dunford J.E., et al. Differences between bisphosphonates in binding affinities for hydroxyapatite. J Biomed Mater Res B 2009, 92B:149-155.
15. Ebetino F.H., Barnett B.L., Russell R.G.G. A computational model delineates differences in hydroxyapatite binding affinities of bisphosphonate. J Bone Miner Res 2005, 20:S259.
16. Josse S., Faucheux C., Soueidan A., Grimandi G., Massiot D., Alonso B., et al. Novel biomaterials for bisphosphonate delivery. Biomaterials 2005, 26:2073-2080.
17. Roussiere H., Montavon G., Laib S., Janvier P., Alonso B., Fayon F., et al. Hybrid materials applied to biotechnologies: coating of calcium phosphates for the design of implants active against bone resorption disorders. J Mater Chem 2005, 15:3869-3875.
18. Roussiere H., Fayon F., Alonso B., Rouillon T., Schnitzler V., Verron E., et al. Reaction of zoledronate with beta-tricalcium phosphate, for the design of potential drug device combined systems. Chem Mater 2008, 20:182-191.
19. Schnitzler V., Fayon F., Despas C., Khairoun I., Mellier C., Rouillon T., et al. Investigation of alendronate-doped apatitic cements as a potential technology for the prevention of osteoporotic hip fractures: critical influence of the drug introduction mode on the in vitro cement properties. Acta Biomater 2011, 7:759-770.
20. Panzavolta S., Torricelli P., Bracci B., Fini M., Bigi A. Alendronate and pamidronate calcium phosphate bone cements: setting properties and in vitro response of osteoblast and osteoclast cells. J Inorg Biochem 2009, 103:101-106.
21. Panzavolta S., Torricelli P., Bracci B., Fini M., Bigi A. Functionalization of biomimetic calcium phosphate bone cements with alendronate. J Inorg Biochem 2010, 104:1099-1106.
22. Ott S.M. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005, 90:1897-1899.
23. Woo S.B., Hande K., Richardson P.G. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005, 353:100-101.
24. Favia G., Pilolli G.P., Maiorano E. Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone 2009, 45:406-413.
25. Pazianas M., Abrahamsen B. Safety of bisphosphonates. Bone 2011, 49:103-110.
26. Boanini E., Gazzano M., Rubini K., Bigi A. Composite nanocrystals provide new insight on alendronate interaction with hydroxyapatite structure. Adv Mater 2007, 19:2499-2502.
27. Peter B., Pioletti D.P., Laïb S., Bujoli B., Pilet P., Janvier P., et al. Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegration. Bone 2005, 36:52-60.
28. Verron E., Gauthier O., Janvier P., Pilet P., Lesoeur J., Bujoli B., et al. In vivo bone augmentation in an osteoporotic environment using bisphosphonate-loaded calcium deficient apatite. Biomaterials 2010, 31:7776-7784.
29. Seshima H., Yoshinari M., Takemoto S., Hattori M., Kawada E., Inoue T., et al. Control of bisphosphonate release using hydroxyapatite granules. J Biomed Mater Res B 2006, 78B:215-221.
30. Boanini E., Torricelli P., Gazzano M., Giardino R., Bigi A. Alendronate-hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells. Biomaterials 2008, 29:790-796.
31. Bigi A., Boanini E., Capuccini C., Fini M., Mihailescu I.N., Ristoscu C., et al. Biofunctional alendronate-hydroxyapatite thin films deposited by matrix assisted pulsed laser evaporation. Biomaterials 2009, 30:6168-6177.
32. Immirzi A. Constrained powder-profile refinement based on generalized coordinates. Application to X-ray data of isotactic polypropylene. Acta Cryst 1980, B36:2378-2385.
33. Brückner S. Profile analysis of X-ray diffraction data from powder polymer samples. Chim Ind 1988, 70:48-53.
34. Meille S.V., Brückner S., Lando J.B. The structure of γ-polypivalolactone: a combined analysis of single-crystal electron diffraction data and powder X-ray diffraction profiles with the Rietveld method. Polymer 1989, 30:786-792.
35. Kuljanin J., Janković I., Nedeljković J., Prstojević D., Marinković V. Spectrophotometric determination of alendronate in pharmaceutical formulations via complex formation with Fe(III) ions. J Pharm Biomed Anal 2002, 28:1215-1220.
36. Klug H.P., Alexander L.E. X-ray diffraction procedures for polycrystalline and amorphous materials 1974, Wiley-Interscience, New York.
37. Kay M.I., Young R.A., Posner A.S. Crystal structure of hydroxyapatite. Nature 1964, 204:1050-1052.
38. Caglioti G., Paoletti A., Ricci F.P. Choice of collimators for a crystal spectrometer for neutron diffraction. Nucl Instrum 1958, 3:223-228.
39. Kempster C.J.E., Lipson H. A rapid method for assessing the number of molecules in the unit cell of an organic crystal. Acta Cryst 1972, B28:3674.
40. Freire E., Vega D.R., Baggio R. Zoledronate complexes. III. Two zoledronate complexes with alkaline earth metals: [Mg(C5H9N2O7P2)2(H2O)2] and [Ca(C5H8N2O7P2)(H2O)]n. Acta Cryst 2010, C66:m166-m170.
41. Fernandez D., Vega D., Goeta A. Alendronate zwitterions bind to calcium cations arranged in columns. Acta Cryst 2003, C59:m543-m545.
42. Robinson J., Cukrowski I., Marques H.M. Modelling the interaction of several bisphosphonates with hydroxyapatite using the generalised AMBER force field. J Mol Struc 2006, 825:134-142.
43. Canepa P., Chiatti F., Corno M., Sakhno Y., Martra G., Ugliengo P. Affinity of hydroxyapatite (001) and (010) surfaces to formic and alendronic acids: a quantum-mechanical and infrared study. Phys Chem Chem Phys 2011, 13:1099-1111.
44. Reinholz G.G., Getz B., Pederson L., Sanders E.S., Subramaniam M., Ingle J.N., et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000, 60:6001-6007.
45. Fromigué O., Body J.J. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 2002, 25:539-546.
46. Koch F.P., Yekta S.S., Merkel C., Ziebart T., Smeets R. The impact of bisphosphonates on the osteoblast proliferation and collagen gene expression in vitro. Head Face Med 2010, 9:6-12.
47. Wood J., Bonjean K., Ruetz S., Bellahcene A., Devy L., Foidart J.M., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002, 302:1055-1061.
48. Mundy G.R., Yoneda T., Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol 2001, 28:35-44.
49. Correia V.de.F., Caldeira C.L., Marques M.M. Cytotoxicity evaluation of sodium alendronate on cultured human periodontal ligament fibroblasts. Dent Traumatol 2006, 22:312-317.
50. Scheper M.A., Badros A., Chaisuparat R., Cullen K.J., Meiller T.F. Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol 2009, 144:667-676.
51. Garcia-Moreno C., Serrano S., Nacher M., Farré M., Díez A., Mariñoso M.L., et al. Effect of alendronate on cultured normal human osteoblasts. Bone 1998, 22:233-239.
52. Corrado A., Neve A., Maruotti N., Gaudio A., Marucci A., Cantatore F.P. Dose-dependent metabolic effect of zoledronate on primary human osteoblastic cell cultures. Exp Rheumatol 2010, 28:873-879.
53. Schindeler A., Little D.G. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro. Biochem Biophys Res Commun 2005, 338:710-716.
54. Agis H., Blei J., Watzek G., Gruber R. Is zoledronate toxic to human periodontal fibroblasts?. J Dent Res 2010, 89:40-45.
55. Im G.I., Qureshi S.A., Kenney J.K., Rubash H.E., Shanbhag A.S. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 2004, 25:4105-4115.
56. Xiong Y., Yang H.J., Feng J., Shi Z.L., Wu L.D. Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells. J Int Med Res 2009, 37:407-416.
57. Shi X., Wang Y., Ren L., Gong Y., Wang D.A. Enhancing alendronate release from a novel PLGA/hydroxyapatite microspheric system for bone repairing applications. Pharm Res 2009, 26:422-430.
58. Schuessele A., Mayr H., Tessmar J., Goepferich A. Enhanced bone morphogenetic protein-2 performance on hydroxyapatite ceramic surfaces. J Biomed Mater ResA 2009, 90A:959-971.
59. Kim Y.H., Kim G.S., Jeong-Hwa B. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Exp Mol Med 2002, 34:145-151.
60. Viereck V., Emons G., Lauck V., Frosch K.H., Blaschke S., Gründker C., et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002, 291:680-686.
61. Enjuanes A., Ruiz-Gaspà S., Peris P., Ozalla D., Álvarez L., Combalia A., et al. The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts. Endocrine 2010, 37:180-186.
62. Giner M., Rios M.J., Montoya M.J., Vázquez M.A., Miranda C., Pérez-Cano R. Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis. Eur J Pharmacol 2011, 650:682-687.
63. Aubin J.E., Bonnelve E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 2000, 11:905-913.
64. Faucheux C., Verron E., Soueidan A., Josse S., Arshad M.D., Janvier P., et al. Controlled release of bisphosphonate from a calcium phosphate biomaterial inhibits osteoclastic resorption in vitro. J Biomed Mater Res A 2009, 89A:46-56.
65. Benford H.L., McGowan N.W., Helfrich M.H., Nuttall M.E., Rogers M.J. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001, 28:465-473.